I would also prefer it to be listed first, but if for a moment I had the presumption of putting myself in Joe's shoes, I would evaluate in sequence:
Do I have sufficient funding to proceed with the development of my plans, without further diluting? Or rather, is Bintai respecting the contract in which it committed itself to fully finance the vaccine? And are the Chinese reliable partners? If so, to both questions, is it better to quote shortly by canceling at least 250 million out of 360 million shares owned or wait for results that can increase the value of Ngio and allow me to cancel fewer shares? At best, however, I don't think we will be listed by February, and many things can happen in these 2 months, including an acceleration in vaccine development, for example with test results made public, with the start of phase 1 / 2, which could significantly increase the valuation by 500 million ... imho